Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma

27 April 2022 : Clinical Research

Lei Wang^1CD, Lei Wang^23DEF, Bo Xiao^4BC, Mingxuan Cui^4CDE, Bo Zhang^4A*

DOI: 10.12659/MSM.934936

Med Sci Monit 2022; 28:e934936

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Comparison of safety and adverse reactions of the 2 groups (case%).

Group	Hypertension	Hand–foot skin reaction	Diarrhea	Nausea	Fatigue	Frequent urination	Dizziness
S	21 (30.0%)	10 (14.3%)	19 (27.1%)	2 (2.9%)	2 (0.4%)	2 (0.4%)	6 (8.6%)
L	18 (45.0%)^*	4 (10.0%)^*	16 (40.0%)^*	1 (2.5%)	1 (0.0%)	1 (0.0%)	4 (10.0%)
S indicates sorafenib treatment and L indicates lenvatinib treatment. ^* Represents

Back to the Article